@American_Heart’s official account for meetings, science news, funding opportunities and membership. RTs/Follows not endorsements. Pump up your career, here.
Congratulations, MedRhythms & Vascudyne 🎉
MedRythyms, based in Portland, Maine, received the Best Business, Audience Choice and Best Overall Awards at the Health Tech Competition during Scientific Sessions 2026! The biotech company is developing a technology platform that combines sensors, software and music to help people improve walking and mobility after stroke or other neurological injury or disease.
Vascudyne, based in St. Paul, Minn., received the Best Science award for its bioengineered blood vessel technology being developed to provide alternatives to harvesting a patient’s leg vein for coronary bypass surgery and to create grafts for children with congenital heart defects that have the potential to grow with them.
The Health Tech Competition, is hosted each year at Scientific Session by the American Heart Association Center for Health Technology & Innovation. Health tech finalists are invited to pitch their solutions in cardiovascular and brain health live before top physicians, investors, industry leaders and VIP judges. The overall winner receives a one-year complimentary membership to the Innovators’ Network as well as other mentorship and networking opportunities.
📷 2026 Health Tech Competition finalists
Pediatric heart failure (HF) arises from structural or functional cardiac disorders that impair ventricular filling and/or ejection. It is a complex condition with heterogeneous presentations driven by diverse etiologies and is associated with substantial morbidity, mortality, and health care burden.
Guideline-directed medical therapy, including angiotensin receptor–neprilysin inhibitors (ARNIs), sodium–glucose cotransporter 2 inhibitors (SGLT2i), and intravenous iron, remains under-investigated in children and are inconsistently prescribed, often requiring clinicians to extrapolate from adult data or practice without formal guidance.
This science advisory details results from a survey of pediatric HF clinicians in the United States and Canada, focusing on prescribing practices, side effects, dosing experience, and clinician perspectives on the use of ARNIs, SGLT2i, and iron replacement therapy in children.
Read the paper and supplemental materials here: https://t.co/FBoMtJ5Es4
The 2026 Guideline for Adult Stroke Rehabilitation and Recovery was recently published.
Here are the top things for occupational therapists to know.
View the paper and supplemental resources here: https://t.co/S4CB0POw56
Peripheral Artery Disease in Acute Care Settings: Diagnosis and Management of Common Presentations and Emergencies: A Scientific Statement From the American Heart Association: @AHAScience@CircAHA
🥸Congratulations to Dr Rymer and Dr Secemsky on great synthesis
😱Summary is below
👇👇👇
⏰ Time's almost up! We’re looking to fund innovative, high-impact research that could lead to critical discoveries or major advancements in cardiovascular and/or cerebrovascular research. Find out more. 👇
Learn about this opportunity here: https://t.co/P3KTXWfb9k
Don't miss this chance to jumpstart your research career.
If you’re in the early years of your first professional appointment, this grant will support your research, training and mentorship to ensure your future success as a research scientist.
Find more information on this opportunity here: https://t.co/HBFu4P3PzY
Heart and brain health are deeply connected. Join us Wednesday, Nov. 18 for Blood Pressure: From Science to Social Impact, the first installment of the Heart-Brain Connection Webinar Series. Together, we'll explore perspectives from research, healthcare and community action to turn knowledge into impact.
@ycommodore , @dralishareed
US Veterans make up more than 5% of the US adult population. Compared with the general US population, Veterans are older, have more comorbidities, and face unique structural barriers, including high rates of rural location and less internet access. With time, the makeup of Veterans is becoming increasingly diverse in race, ethnicity, age, gender, and military exposure history.
Veterans receiving care in the Veterans Administration (VA) have higher rates of obesity, diabetes, hyperlipidemia, hypertension, and sleep disorders compared to the general population. Data from the Million Veteran Program show that fewer than 5% of Veterans achieve optimal cardiovascular health based on the American Heart Association’s Life’s Essential 8 domains, which in turn has been associated with reduced life expectancy.
✍🏼 @yuanneal @AIDALMARZOOQ @wccushman@jenmartinsleeps@Lisa_Jackson_MD
📷 Meeting the cardiovascular health promotion needs of US veterans: challenges and responses.
https://t.co/9TM4zzc6DM
AI is transforming cardiovascular care at the point of care, creating new opportunities to close the gap between scientific discovery and patient care. At #ScientificSessions26, past American Heart Association President Bob Harrington, MD, FAHA and OpenAI's Nate Gross, MD, explored how AI can help accelerate the future of medicine. 💡
@HeartBobH, @NG
As #ScientificSessions26 comes to a close, we celebrate the science, innovation and collaboration that continue to shape the future of cardiovascular and brain health.
Now, we look ahead to a historic milestone.
Join us in Boston for the 100th Scientific Sessions, Nov. 5-8, 2027.
@HeartDocSadiya@bnallamo
#ScientificSessions27
SYNCHRONIZE-CVOT results presented at #ScientificSessions26
In adults with obesity and established cardiovascular or chronic kidney disease, or increased cardiovascular risk, survodutide was non-inferior to placebo for a composite of cardiovascular death, non-fatal cardiovascular events, coronary revascularization, and heart failure events, while also improving cardiometabolic markers.
🧵/ Late breaking science results from #ScientificSessions26 will be posted to this thread at the time of presentation:
ZEUS
Lp(a) HORIZON
OCEANIC-STROKE
REDUCE
OPTIMAL-Stroke
STREAM
Yoga-CaRe HF Trial
SUPERIOR
RACE-CARS
ATTAIN-OSA
SYNCHRONIZE-CVOT
⬇️
(bookmark this post)
ATTAIN-OSA results presented at #ScientificSessions26
Among adults with moderate-to-severe OSA and overweight or obesity without diabetes, orforglipron significantly reduced apnea-hypopnea index compared with placebo at 52 weeks, both in participants using and not using positive airway pressure therapy.
SYNCHRONIZE-CVOT results presented at #ScientificSessions26
In adults with obesity and established cardiovascular or chronic kidney disease, or increased cardiovascular risk, survodutide was non-inferior to placebo for a composite of cardiovascular death, non-fatal cardiovascular events, coronary revascularization, and heart failure events, while also improving cardiometabolic markers.
ATTAIN-OSA results presented at #ScientificSessions26
Among adults with moderate-to-severe OSA and overweight or obesity without diabetes, orforglipron significantly reduced apnea-hypopnea index compared with placebo at 52 weeks, both in participants using and not using positive airway pressure therapy.